Skip to main content

Table 2 Incidence of CYP3A4-related potential DDIs by number of drugs taken

From: Characteristics of CYP3A4-related potential drug-drug interactions in outpatients receiving prescriptions from multiple clinical departments

 

Number of drugs taken

Subdivided control data

Multiple clinical departments

P-value

Number of patients

less than 6

516

128

 

6 or more

128

244

 

Number of drugs taken

less than 6

3.0 ± 1.0

4.3 ± 0.8

 < 0.01*, a

6 or more

7.5 ± 1.7

8.7 ± 2.4

 < 0.01*, a

Number of drugs involved CYP3A4-related potential DDIs

less than 6

1.4 ± 1.0

2.1 ± 1.2

 < 0.01*, a

6 or more

3.5 ± 1.6

4.0 ± 1.7

 < 0.01*, a

Incidence of CYP3A4-related potential DDI due to two or more drugs

less than 6

43.2%

71.1%

 < 0.01*, b

6 or more

89.8%

94.7%

0.090b

Incidence of CYP3A4-related potential DDI due to three or more drugs

less than 6

13.6%

35.2%

 < 0.01*, b

6 or more

74.2%

81.2%

0.142b

  1. Values for the number of drugs is shown as the mean ± standard deviation
  2. DDIs Drug-drug interactions
  3. Prescriptions subdivided by clinical department, which containing two or more of drugs, were used as control data for the number of drugs involved and incidence of CYP3A4-related potential DDIs
  4. *P < 0.05, aMann-Whitney U test, bchi-square test